Sartorius to Acquire Albumedix, Strengthening its Portfolio of Innovative Advanced Therapy Solutions
Göttingen, August 8, 2022: The life science group Sartorius,
through its French listed subgroup Sartorius Stedim Biotech, has agreed
to acquire 100 percent of Albumedix Ltd. from private investors. The
Nottingham, UK-based company provides best-in-class recombinant
albumin-based solutions. Recombinant human albumin is an important
component for the biopharmaceutical industry required for various
applications, for example as an animal-free additive to cell culture
media and for the stabilization of vaccines and viral therapies. The
business, founded in 1984, has more than 100 employees and is expected
to generate revenue of approximately £33 million in 2022 with a
significant double-digit EBITDA margin. The agreed purchase price
amounts to approximately £415 million. The transaction is subject to
regulatory approval and is expected to close before the end of the third
quarter of 2022.
More info >> |